San Diego’s Biocept Inc. has struck a new deal with Teneovita Medical under which the Vancouver-based provider will market and distribute Biocept's liquid biopsy testing services.
The tests, called Target Selector, will be sold to hospitals, individual oncology practices, and other cancer centers in Canada.
Financial terms of the deal were not disclosed.
The Target Selector offering includes tests that detect a variety of cancer-associated biomarkers in either circulating tumor cells or circulating cell-free DNA.
Over the last several months, Biocept has made similar agreements in Israel, Mexico and the Philippines, making its tests available to patients in international markets.